An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.

Dionisia QuirogaRobert WesolowskiSara ZelinskasAshley PinetteBrooke BennerEmily SchwarzHimanshu SavardekarCourtney JohnsonAndrew StiffLianbo YuErin MacraeMaryam LustbergEwa MrozekBhuvaneswari RamaswamyWilliam E Carson

Published in: Cancer control : journal of the Moffitt Cancer Center (2024)

CpG ODN and trastuzumab treatment of metastatic HER2 + breast cancer was safe but was not tolerable for all patients. This combination did induce potentially predictive immune profile changes in treated patients with metastatic HER2 + breast cancer, the significance of which needs to be further explored.

Keyphrases

newly diagnosed
dna methylation
end stage renal disease
epidermal growth factor receptor
ejection fraction
small cell lung cancer
squamous cell carcinoma
prognostic factors
gene expression
metastatic breast cancer
young adults
replacement therapy
smoking cessation